 Forward Pharma AS FWP the Company today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This follows the development in the Companys American Depositary Shares ADSs or shares price after the Settlement and License Agreement with Biogen, and the significant return of capital to its shareholders in 2017. On June 21, 2019, the Company received a written notice from the Nasdaq Stock Market Nasdaq indicating that the Company is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum Market Value of Publicly Held Shares MVPHS of 5,000,000, as set forth in Nasdaq Listing Rule 5450b1C the MVPHS Notice. 